Spring Bank Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Milford MA United States (2002)
Status: Acquired by F-star Delta Limited (2020) → now InvoX (2022)

Organization Overview

First Clinical Trial
2013
NCT01803308
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Spring Bank Pharmaceuticals | Spring Bank Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

inarigivir (7 trials)

tenofovir alafenamide (genvoya) (2 trials)

Drugs in Phase 1 Trials (3)

midazolam (versed) (1 trial)

nivolumab (opdivo) (1 trial)

sb 11285 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis C (Phase 1)

Hepatitis, Chronic (Phase 2)

Infections (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5